Resolvyx Pharmaceuticals, Inc. and Celtic Therapeutics Enter Final Agreement in Ophthalmology
1/10/2011 6:23:25 AM
More...
|
Resolvyx Pharmaceuticals, Inc. and Celtic Therapeutics Ink Dry Eye Deal
10/26/2010 7:58:47 AM
More...
|
Resolvyx Pharmaceuticals, Inc. Presents Data Demonstrating Potential for Resolvin Therapeutics to Treat Corneal and Retinal Eye Diseases at ARVO 2010 Meeting
5/6/2010 11:17:18 AM
More...
|
Resolvyx Pharmaceuticals, Inc. Granted U.S. Patent for the First Resolvin Therapeutic to Enter Human Trials
9/18/2009 9:53:04 AM
More...
|
Resolvyx Pharmaceuticals, Inc. Announces Positive Data from Phase 2 Clinical Trial of the Resolvin RX-10045 in Patients with Dry Eye Syndrome
8/24/2009 6:27:58 AM
More...
|
Resolvyx Pharmaceuticals, Inc. Initiates Phase I Clinical Trial of Novel Resolvin, RX-10001, for Asthma and Inflammatory Diseases
6/23/2009 9:31:05 AM
More...
|
Resolvyx Pharmaceuticals, Inc. Presents Data Demonstrating Potential for Resolvin Therapeutics to Treat Corneal and Retinal Eye Diseases at Association for Research in Vision & Ophthalmology 2009 Meeting
5/6/2009 9:05:22 AM
More...
|
Resolvyx Pharmaceuticals, Inc. to Present Data on Novel Resolvin Drug Candidates for Eye Disease at ARVO Annual Meeting
4/27/2009 10:51:28 AM
More...
|
Resolvyx Pharmaceuticals, Inc. Appoints Industry Leader Philip Vickers as Chief Scientific Officer
4/15/2009 9:22:57 AM
More...
|
Resolvyx Pharmaceuticals, Inc. Announces Initiation of Phase I/II Clinical trial of Novel Resolvin Therapeutic RX-10045 in Patients with Dry Eye
12/18/2008 10:58:16 AM
More...
|
|